Last reviewed · How we verify

Prenatal

Stony Brook University · FDA-approved active Small molecule Quality 8/100

Prenatal, marketed by Stony Brook University, holds a niche position in the prenatal supplement market without direct revenue figures disclosed. A key strength lies in its composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the potential increase in competition post-patent expiry, which could erode market share.

At a glance

Generic namePrenatal
SponsorStony Brook University
Drug classVitamin C [EPC]
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Boxed warnings

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: